title: [Drooling therapy in children with neurological disorders].
abstract: BACKGROUND
  Drooling is the inability to retain saliva in the mouth and its progression to the digestive tract, being a common problem in pediatric patients with neurological disorders. Three different treatment options are available.
  
  
  OBJECTIVE
  To assess the effectiveness and safety of trihexyphenidyl, scopolamine and botulinum toxin infiltration in the treatment of drooling in children with neurological disorders.
  
  
  METHODS
  This is an open and prospective type study. We include patients treated in the Neurology Service that present excessive drooling, affecting their quality of life, between 2009 and 2013.
  
  
  RESULTS
  We enrolled 46 patients in the study. The treatment with oral trihexyphenidyl was indicated in 46, obtaining good result in 15 (32.6%), three with temporary effect and the rest with lasting effect. Three patients presented side effects (6.5%). Four out of 11 (36.36%) patients treated with scopolamine patch had beneficial effects. One was withdrawn due to lack of efficacy and six due to side effects. Twenty-five patients were infiltrated with botulinum toxin, with a significant decrease of drooling in 16 patients (64%) after the first injection. We observed no significant changes in nine patients. Only one out of 25 showed side effects (mild dysphagia).
  
  
  CONCLUSIONS
  Currently there is not a fully effective therapeutic option for drooling. We recommend starting treatment with trihexyphenidyl. A second option could be the scopolamine patch and botulinum toxin as a third option. Botulinum toxin infiltration in salivary glands is shown as an effective and safe alternative in our study.
authors.forename: M Andrea
authors.initials: MA
authors.lastname: Táboas-Pereira
authors.forename: Cecilia
authors.initials: C
authors.lastname: Paredes-Mercado
authors.forename: Xènia
authors.initials: X
authors.lastname: Alonso-Curcó
authors.forename: Joaquim
authors.initials: J
authors.lastname: Badosa-Pagès
authors.forename: Jordi
authors.initials: J
authors.lastname: Muchart
authors.affiliation: Hospital Universitari Sant Joan de Deu, Esplugues de Llobregat, Espana.
authors.forename: Pilar
authors.initials: P
authors.lastname: Póo
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000627:therapeutic use*; D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000150:complications; D011446:Prospective Studies; D012601:Scopolamine / Q000627:therapeutic use*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology; D014282:Trihexyphenidyl / Q000627:therapeutic use*
chemical_list: D065087:Acetylcholine Release Inhibitors; D018727:Muscarinic Antagonists; D014282:Trihexyphenidyl; D012601:Scopolamine; D019274:Botulinum Toxins, Type A